These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10845939)

  • 21. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
    Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
    Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML.
    Serrano J; Román J; Castillejo JA; Sánchez J; Navarro JA; Martín C; Herrera C; Torres A
    Bone Marrow Transplant; 1998 Sep; 22(6):599-601. PubMed ID: 9758352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-Cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires.
    Godthelp BC; van Tol MJ; Vossen JM; van Den Elsen PJ
    Blood; 1999 Dec; 94(12):4358-69. PubMed ID: 10590082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
    Spencer A; Szydlo RM; Brookes PA; Kaminski E; Rule S; van Rhee F; Ward KN; Hale G; Waldmann H; Hows JM; Batchelor JR; Goldman JM
    Blood; 1995 Nov; 86(9):3590-7. PubMed ID: 7579468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
    Gale RP; Horowitz MM
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; De'Arce M; McCann SR
    Leukemia; 1997 Apr; 11 Suppl 3():512-5. PubMed ID: 9209441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia.
    Mackinnon S; Barnett L; Heller G; O'Reilly RJ
    Blood; 1994 Jun; 83(11):3409-16. PubMed ID: 8193379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal analysis of T-cell receptor variable beta chain repertoire in patients with acute graft-versus-host disease after allogeneic stem cell transplantation.
    Liu C; He M; Rooney B; Kepler TB; Chao NJ
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):335-45. PubMed ID: 16503503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
    Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
    Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
    Bellucci R; Alyea EP; Weller E; Chillemi A; Hochberg E; Wu CJ; Canning C; Schlossman R; Soiffer RJ; Anderson KC; Ritz J
    Blood; 2002 Jun; 99(12):4610-7. PubMed ID: 12036895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
    Soiffer RJ; Alyea EP; Hochberg E; Wu C; Canning C; Parikh B; Zahrieh D; Webb I; Antin J; Ritz J
    Biol Blood Marrow Transplant; 2002; 8(11):625-32. PubMed ID: 12463482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia.
    Elmaagacli AH; Peceny R; Steckel N; Trenschel R; Ottinger H; Grosse-Wilde H; Schaefer UW; Beelen DW
    Blood; 2003 Jan; 101(2):446-53. PubMed ID: 12393406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
    Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M
    Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia.
    Delage R; Ritz J; Anderson KC
    Hematol Oncol Clin North Am; 1990 Apr; 4(2):369-88. PubMed ID: 2182597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
    Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
    Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.